维普中文期刊产品整合服务
35篇 您的检索式:作者名="Plimack"
    题名 作者 年代 出处 被引量
1Decitabine and its role in the treatment of hematopoietic malignancies显示文摘Plimack ER Kantarjian HM Issa JP 2007Leuk Lymphoma2007,48,8:1
2Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy显示文摘Daniel Canter Rosalia Viterbo Alexander Kutikov Yu-Ning Wong Elizabeth Plimack Fang Zhu Megan Oblaczynski Raffi Berberian David Y.T. Chen Richard E. Greenberg Robert G. Uzzo Stephen A. Boorjian 2011Urology2011,,1:1
3Bi- weekly 72-h 9-aminocamptothecin infusion as second-line therapy for ovarian cancinoma : Phase II study of the new york gynecologic oncology group and the eastern cooperative oncology group 显示文摘HOCHSTER H PLIMACK E R RUNOWICZ C D 2004J Clin Oncol2004,22,1:1
4Phase Istudy of nivolumab in combination with ipilimumab (IPI) inmetastatic renal cell carcinoma (mRCC) 显示文摘HAMMERS H PLIMACK ER INFANTE JR 2014BJU Int2014,114,111:1
5Patterns of disease pro- gression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon 显示文摘Plimack E R Tannir N Lin E 2009Cancer2009,115,9:1
6Combining epigenetic and cytotoxic therapy in the treatment of solid tumors显示文摘PLIMACK E R STEWART D J ISSA J P 2007J Clin Oncol2007,25,29:1
7A phase I b multi-cohort study of MK-3472 in subject with advanced solid tumors显示文摘Plimack ER Bellmunt J Gupta S 2015J Clin Oncol2015,33,:1
8Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadju- vant treatment for muscle-invasive bladder cancer: re- sults of a multicenter phase II study with molecular correlates of response and toxicity显示文摘Plimack E R Hoffman-Censits J H Viterbo R 2014J Clin Oncol2014,32,18:1
9Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials显示文摘GODWIN JL ZIBELMAN M PLIMACK ER 2014Discov Med2014,18,101:1
10Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer:An NYGOG and ECOG study显示文摘Hochster H S Plimack E R Mandeli J 2006Gynecol Oncol2006,100,2:1
11Prolonged topotecan infusion wish cisplatin in the firt-line treatment of ovarian cancer:An NYGOG and ECOG study显示文摘Hoochster HS Plimack ER Mandeli J 2006Gynecol Oncol2006,100,2:1
12Nivolumab (anti - PD - 1; BMS - 936558, ONO - 4538 ) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)显示文摘AMIN A PLIMACK E R INFANTE J R 2014J Clin Oncol2014,32,15:1
13Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle - invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity 显示文摘Plimack ER Hoffman - Censits JH Viterbo R 2014J Clin Oncol2014,32,18:1
14Decitabine and its role in the treatment of hematopoietic malignancies显示文摘Plimack ER Kantarjian HM Issa JP 2007Leuk Lymphoma2007,48,8:1
15Combining epigenetic and cy- totoxic therapy in the treatment of solid tumors显示文摘Plimack ER Stewart DJ Issa JP 2007J Cli Oncol2007,25,29:1
16Lymphopenia is an inde- pendent predictor of inferior outcome in clear cell renal carcinoma 显示文摘Saroha S Uzzo ]RG Plimack ER 2013The J urology2013,,:1
17A phase I study of temsirolim- us and bryostatin- 1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma显示文摘Plimack ER Tan T Wong YN 2014Oncologist2014,19,4:1
18Decitabine and its role inthe treatment of hematopoietic malignancies显示文摘Plimack ER Kantarjian HM Issa JP 2007Leuk Lymphoma2007,48,8:1
19Nivolumab (anti - PD - 1 ; BMS -936558,ONO -4538) in combination with sunitinib or peizopanib in patients ( pts) with metastatic renal cell carcinoma (mRCC)显示文摘Amin A Plimack ER Infante JR 2014J Clin Oncol2014,32,15:1
20Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer 显示文摘Plimack ER Dunbrack RL Brennan TA 2015Eur Urol2015,68,6:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费